Update in clinical and mouse microbiota research in allogeneic haematopoietic cell transplantation.
Update in clinical and mouse microbiota research in allogeneic haematopoietic cell transplantation.
复制标题
DOI:
10.1097/moh.0000000000000616
复制
发表时间:
2020-11
影响因子:
3.2
通讯作者:
Peled JU
中科院分区:
文献类型:
--
作者:
Lindner S;Peled JU
The intestinal microbiota plays a critical role in intestinal homeostasis and immune regulation and has been recognized as a predictor of clinical outcome in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and specifically a determinant of the severity of graft-versus-host disease (GVHD) in mouse models. As GVHD is the most important cause of non-relapse mortality (NRM) after allo-HCT, understanding the mechanisms by which modifying the microbiota may prevent or decrease the severity of GVHD would represent an important advance. Microbiota injury was observed globally and higher diversity at periengraftment was associated with lower mortality. Lactose is a dietary factor that promotes post-allo-HCT Enterococcus expansion, which is itself associated with mortality from GVHD in patients and exacerbates GVHD in mice. Bacterial and fungal bloodstream infections are preceded by intestinal colonization with a corresponding organism, supporting the gut as a source for many bloodstream infections. Metabolomic profiling studies showed that GVHD is associated with changes in fecal and plasma microbiota-derived molecules. In this review, we highlight some of the most recent and important findings in clinical and mouse microbiota research as it relates to allo-HCT. Many of these are already being translated into clinical trials that have the potential to change the future practice in the care of patients.